Antitrust

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

At CES 2026, a new $39,900 personal eVTOL promises flight for all, no license needed. But can it safely navigate regulatory and public trust hurdles?

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

After 16 years, Chief Legal Officer Anthony Green announces his retirement, leaving a void at the top and questions about Annaly's future governance.

The National Police Federation slams a report backing a provincial police force, citing high costs, low public support, and broken promises.

SBA head Kelly Loeffler gives her 2025 pay to charity, a move that mixes disaster relief with support for controversial political group Turning Point USA.

A new class action lawsuit accuses medical device firm Integer Holdings of hiding poor sales while touting growth, leading to a major stock drop.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

Amid rising legal threats, a new coalition offers free legal aid to Canadian journalists, aiming to protect press freedom and empower local reporting.

Don't get stumped by risky contractors. A tree care expert shares crucial tips on licensing, insurance, and what to ask before you hire any service.

The CT Plan selects DataCT as its independent administrator, a critical step in a sweeping SEC-mandated overhaul of market data set for 2027.

BTCC's integration with TradingView signals a major industry shift, bringing professional-grade tools and seamless execution to the crypto futures market.

Regulatory filings reveal Balyasny Asset Management's strategic trades in Avadel Pharma, offering a glimpse into the high-stakes bidding war with Alkermes.

Beyond bureaucracy, a federal push for bilingual services aims to dismantle linguistic barriers, impacting health equity for minority communities across Canada.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

A government crackdown on clergy and a top businessman raises serious questions about Armenia's judicial independence, spooking investors and allies alike.

In a powerful move, Ashkenazy Acquisition Corp. acquires a major Chicago retail center, part of a $750M spree that defies market doomsayers.